Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Legal & General announces £500m buyback as annual profits rise

(Sharecast News) - Financial services group Legal & General has announced plans to buy back £500m of shares this year after a strong financial performance in 2024, as part of plans to return more than £5bn to shareholders within three years. "We stated at our Capital Markets Event that we intended to return more to shareholders and that is exactly what we are doing," said chief executive António Simões. "Our clear capital allocation framework supports our plan to return over £5 billion over the next three years, through dividends and buybacks," he said.

The share repurchase follows a £200m buyback in 2024 and an already announced £1bn buyback which will commence after the sale of its US protection business. In total, the £5bn, three-year distribution will equal to around 40% of L&G's market capitalisation.

The company also declared a final dividend of 15.36p, taking the full-year payout to 21.36p, up 5% over 2023. L&G intends to scale back dividend-per-share growth to 2% per annum between 2025 and 2027.

Core operating profits were up 6% last year at £1.62bn - in line with recent guidance - with a decline in asset management profits outweighed by growth in the retail and institutional retirement divisions.

For 2025, the asset management division is said to have had a "positive start" to the year with flows into higher margin products. L&G also expects strong volumes in institutional retirement and a "thriving" retail annuities market.

"Looking ahead, our momentum demonstrates why we are confident in our ability to deliver on our ambitious targets, directing our capital and expertise where they can create lasting value, and making a meaningful impact for customers, shareholders and communities," Simões said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.